The Drug-Induced Respiratory Disease Website and App

Cytosine arabinoside - Aracytine - Cytarabine - Ara-C

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

This complications likely appears to be related to the dose or Ara-C (PMID 25689584)

Publications

Kopterides P, Lignos M, Mentzelopoulos S, Armaganidis A, Pappa V

Cytarabine-induced lung injury: case report.

Anti-cancer drugs. 2005;16(7):743-5

Haupt HM, Hutchins GM, Moore GW

Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.

The American journal of medicine. 1981;70(2):256-61

Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB

Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.

Cancer. 1990;65(5):1079-84